Kite Pharma, a GILEAD company, has announced that the FDA has approved TECARTUS® (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The approval is based on the ZUMA-3 study: a global, multi-center, single-arm open label study. 65% of patients achieved complete remission with incomplete haematological recovery at a median effective follow-up of 12.3 months.